Zacks Research Research Analysts Lift Earnings Estimates for Haemonetics Co. (NYSE:HAE)

Haemonetics Co. (NYSE:HAE) – Analysts at Zacks Research boosted their Q3 2025 earnings per share estimates for shares of Haemonetics in a research report issued to clients and investors on Wednesday, August 28th. Zacks Research analyst R. Department now expects that the medical instruments supplier will earn $1.22 per share for the quarter, up from their prior estimate of $1.20. The consensus estimate for Haemonetics’ current full-year earnings is $4.58 per share. Zacks Research also issued estimates for Haemonetics’ Q4 2025 earnings at $1.21 EPS, FY2025 earnings at $4.55 EPS, Q1 2026 earnings at $1.19 EPS, Q3 2026 earnings at $1.22 EPS, Q4 2026 earnings at $1.40 EPS and FY2026 earnings at $5.10 EPS.

Other equities analysts have also recently issued reports about the company. Barrington Research increased their price target on Haemonetics from $107.00 to $108.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Citigroup cut their target price on Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a report on Thursday, August 22nd. JMP Securities reiterated a “market outperform” rating and issued a $125.00 target price on shares of Haemonetics in a report on Tuesday, August 13th. Finally, Needham & Company LLC upgraded Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 target price on the stock in a report on Wednesday, June 12th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $107.50.

Haemonetics Price Performance

Haemonetics stock opened at $75.07 on Monday. The stock has a market capitalization of $3.83 billion, a price-to-earnings ratio of 32.78, a PEG ratio of 1.38 and a beta of 0.29. Haemonetics has a 52-week low of $70.74 and a 52-week high of $97.97. The stock’s 50 day moving average price is $82.91 and its two-hundred day moving average price is $84.00. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.33 and a current ratio of 3.76.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.01). The business had revenue of $336.17 million for the quarter, compared to the consensus estimate of $335.08 million. Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. Haemonetics’s quarterly revenue was up 8.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.05 earnings per share.

Institutional Investors Weigh In On Haemonetics

Large investors have recently made changes to their positions in the business. Quarry LP purchased a new stake in Haemonetics in the 2nd quarter worth about $39,000. TFO Wealth Partners LLC boosted its stake in Haemonetics by 29,450.0% in the 4th quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 589 shares during the period. Covestor Ltd boosted its stake in Haemonetics by 184.8% in the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock worth $58,000 after purchasing an additional 438 shares during the period. Daiwa Securities Group Inc. bought a new position in Haemonetics in the 2nd quarter worth about $82,000. Finally, Canada Pension Plan Investment Board bought a new position in Haemonetics in the 2nd quarter worth about $83,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Haemonetics

In related news, insider Stewart W. Strong sold 4,312 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $91.15, for a total value of $393,038.80. Following the completion of the sale, the insider now directly owns 18,196 shares of the company’s stock, valued at approximately $1,658,565.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Stewart W. Strong sold 4,312 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $91.15, for a total value of $393,038.80. Following the completion of the sale, the insider now directly owns 18,196 shares of the company’s stock, valued at approximately $1,658,565.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Anila Lingamneni sold 2,136 shares of the firm’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $90.00, for a total value of $192,240.00. Following the sale, the executive vice president now directly owns 21,410 shares of the company’s stock, valued at $1,926,900. The disclosure for this sale can be found here. 1.80% of the stock is currently owned by insiders.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.